scholarly journals p53 upregulated mediator of apoptosis (Puma) deficiency increases survival of adult neural stem cells generated physiologically in the hippocampus, but does not protect stem cells generated in surplus after an excitotoxic lesion

Author(s):  
Eva C. Bunk ◽  
Hans-Georg König ◽  
Jochen H.M. Prehn ◽  
Brian P. Kirby

AbstractObjectivesNeurogenesis occurs in the mammalian brain throughout adulthood and increases in response to metabolic, toxic or traumatic insults. To remove potentially superfluous or unwanted neural stem cells/neuronal progenitors, their rate of proliferation and differentiation is fine-tuned against their rate of apoptosis. Apoptosis requires the transcriptional and posttranslational activation of Bcl-2-homolgy domain 3 (BH3)-only proteins. Previously, we demonstrated that the BH3-only protein p53-upregulated mediator of apoptosis (Puma) controls the physiological rate of apoptosis of neural precursor cells in the adult mouse hippocampus. Puma’s role in controlling a lesion-induced increase in neural stem cells is currently not known.MethodsWe employed a model of local, N-methyl-D-asparte (NMDA)-induced excitotoxic injury to the CA1 hippocampal subfield and immunofluorescence labelling to produce increased neural stem cell proliferation/ neurogenesis in the dentate gyrus at two survival times following the excitotoxic lesion.ResultsDeletion of puma failed to rescue any NMDA-induced increase in adult born cells as assessed by BrdU or Doublecortin labelling in the long-term. No difference in the proportion of BrdU/NeuN-positive cells comparing the different genotypes and treatments suggested that the phenotypic fate of the cells was preserved regardless of the genotype and the treatment.ConclusionsWhile neurogenesis is up-regulated in puma-deficient animals following NMDA-induced excitotoxicity to the hippocampal CA1 subfield, puma deficiency could not protect this surplus of newly generated cells from apoptotic cell death.

2021 ◽  
Vol 170 (4) ◽  
pp. 522-527
Author(s):  
G. N. Zyuz’kov ◽  
L. A. Miroshnichenko ◽  
T. Yu. Polyakova ◽  
V. V. Zhdanov ◽  
E. V. Simanina ◽  
...  

2021 ◽  
Vol 28 ◽  
Author(s):  
Han Gao ◽  
Ningjing Huang ◽  
Weiwei Wang ◽  
Lingling Zhang ◽  
Li Cai ◽  
...  

Author(s):  
Ning-Ning Cai ◽  
Qi Geng ◽  
Yu Jiang ◽  
Wen-Qian Zhu ◽  
Rui Yang ◽  
...  

Heliyon ◽  
2017 ◽  
Vol 3 (6) ◽  
pp. e00318 ◽  
Author(s):  
Melanie Bender ◽  
Lisa Schwind ◽  
David Grundmann ◽  
Monika Martin ◽  
Markus Klotz ◽  
...  

2014 ◽  
Vol 38 (1) ◽  
pp. 74-78 ◽  
Author(s):  
Shuang‐Qing Chen ◽  
Qing Cai ◽  
Yu‐Ying Shen ◽  
Xiu‐Ying Cai ◽  
Hai‐Ying Lei

2020 ◽  
Vol 168 (3) ◽  
pp. 356-360 ◽  
Author(s):  
G. N. Zyuz’kov ◽  
L. A. Miroshnichenko ◽  
T. Yu. Polyakova ◽  
L. A. Stavrova ◽  
E. V. Simanina ◽  
...  

2020 ◽  
Author(s):  
Huanhuan Sha ◽  
Peipei Peng ◽  
Bing Li ◽  
Guohua Wei ◽  
Juan Wang ◽  
...  

Abstract Background: Recently, the number of neonatal patients receiving surgery under general anesthesia has increased. Ketamine disrupts the proliferation and differentiation of developing neural stem cells (NSCs). Therefore, the safe use of ketamine in pediatric anesthesia has been an issue of increasing concern among anesthesiologists and the children’s parents. Dexmedetomidine (DEX) is widely used in sedation, as an antianxiety agent and for analgesia. DEX has recently been shown to provide neuroprotection against anesthetic-induced neurotoxicity in the developing brain. The aim of this in vivo study was to investigate whether DEX exerted neuroprotective effects on the proliferation and differentiation of NSCs in the subventricular zone (SVZ) following neonatal ketamine exposure. Methods: Postnatal day 7 (PND-7) male Sprague-Dawley rats were equally divided into the following 5 groups: Control group (n=8), Ketamine group (n=8), 1 μg/kg DEX+Ketamine group (n=8), 5 μg/kg DEX+Ketamine group (n=8) and 10 μg/kg DEX+Ketamine group (n=8). The proliferation and differentiation of NSCs in the SVZ were assessed using immunostaining with BrdU incorporation. The levels of Nestin and β-tubulin III in the SVZ were measured using Western blot analyses. Apoptosis was assessed by detecting the levels of the cleaved caspase-3 protein using Western blotting. Results: Neonatal ketamine exposure significantly inhibited NSC proliferation and astrocytic differentiation in the SVZ, and neuronal differentiation was markedly increased. Furthermore, pretreatment with moderate (5 μg/kg) or high doses (10 μg/kg) of DEX reversed the ketamine-induced disturbances in the proliferation and differentiation of NSCs. Meanwhile, neonatal ketamine exposure significantly decreased the expression of Nestin and increased the expression of β-tubulin III in the SVZ compared with the Control group. Treatment with 10 μg/kg DEX notably reversed the ketamine-induced changes in the levels of Nestin and β-tubulin III. In addition, a pretreatment with 10 μg/kg DEX before ketamine anesthesia prevented apoptosis in the SVZ induced by neonatal ketamine exposure. Conclusions: Based on our findings, DEX may exert neuroprotective effects on the proliferation and differentiation of NSCs in the SVZ of neonatal rats in a repeated ketamine anesthesia model.


Sign in / Sign up

Export Citation Format

Share Document